These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20810568)

  • 1. Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target.
    Marlow LA; D'Innocenzi J; Zhang Y; Rohl SD; Cooper SJ; Sebo T; Grant C; McIver B; Kasperbauer JL; Wadsworth JT; Casler JD; Kennedy PW; Highsmith WE; Clark O; Milosevic D; Netzel B; Cradic K; Arora S; Beaudry C; Grebe SK; Silverberg ML; Azorsa DO; Smallridge RC; Copland JA
    J Clin Endocrinol Metab; 2010 Dec; 95(12):5338-47. PubMed ID: 20810568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth.
    Marlow LA; Reynolds LA; Cleland AS; Cooper SJ; Gumz ML; Kurakata S; Fujiwara K; Zhang Y; Sebo T; Grant C; McIver B; Wadsworth JT; Radisky DC; Smallridge RC; Copland JA
    Cancer Res; 2009 Feb; 69(4):1536-44. PubMed ID: 19208833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.
    Marlow LA; Bok I; Smallridge RC; Copland JA
    Endocr Relat Cancer; 2015 Oct; 22(5):777-92. PubMed ID: 26206775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the RhoB signaling pathway by thyroid hormone receptor β in thyroid cancer cells.
    Ichijo S; Furuya F; Shimura H; Hayashi Y; Takahashi K; Ohta K; Kobayashi T; Kitamura K
    PLoS One; 2014; 9(12):e116252. PubMed ID: 25548921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
    Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
    Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E
    Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity.
    Maniakas A; Henderson YC; Hei H; Peng S; Chen Y; Jiang Y; Ji S; Cardenas M; Chiu Y; Bell D; Williams MD; Hofmann MC; Scherer SE; Wheeler DA; Busaidy NL; Dadu R; Wang JR; Cabanillas ME; Zafereo M; Johnson FM; Lai SY
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4652-e4665. PubMed ID: 34147031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
    Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
    Ishihara S; Onoda N; Noda S; Asano Y; Tauchi Y; Morisaki T; Kashiwagi S; Takashima T; Ohira M
    Int J Oncol; 2019 Nov; 55(5):1069-1076. PubMed ID: 31545405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.
    Zhang L; Boufraqech M; Lake R; Kebebew E
    Oncotarget; 2016 Mar; 7(13):16517-28. PubMed ID: 26934320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
    Aiello A; Pandini G; Frasca F; Conte E; Murabito A; Sacco A; Genua M; Vigneri R; Belfiore A
    Endocrinology; 2006 Sep; 147(9):4463-75. PubMed ID: 16777971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.
    Schiff BA; McMurphy AB; Jasser SA; Younes MN; Doan D; Yigitbasi OG; Kim S; Zhou G; Mandal M; Bekele BN; Holsinger FC; Sherman SI; Yeung SC; El-Naggar AK; Myers JN
    Clin Cancer Res; 2004 Dec; 10(24):8594-602. PubMed ID: 15623643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression.
    Yan P; Su Z; Zhang Z; Gao T
    Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.
    Schweppe RE; Pozdeyev N; Pike LA; Korch C; Zhou Q; Sams SB; Sharma V; Pugazhenthi U; Raeburn C; Albuja-Cruz MB; Reigan P; LaBarbera DV; Landa I; Knauf JA; Fagin JA; Haugen BR
    Mol Cancer Res; 2019 May; 17(5):1036-1048. PubMed ID: 30733375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of nutraceuticals on anaplastic thyroid cancer cells.
    Allegri L; Rosignolo F; Mio C; Filetti S; Baldan F; Damante G
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):285-294. PubMed ID: 29197967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma.
    Hayashi N; Nakamori S; Hiraoka N; Tsujie M; Xundi X; Takano T; Amino N; Sakon M; Monden M
    Int J Oncol; 2004 Jan; 24(1):89-95. PubMed ID: 14654945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors.
    Onoda N; Nakamura M; Aomatsu N; Noda S; Kashiwagi S; Hirakawa K
    World J Surg; 2014 Mar; 38(3):688-95. PubMed ID: 24357248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression.
    Sheng W; Chen Y; Gong Y; Dong T; Zhang B; Gao W
    Oncol Rep; 2016 Dec; 36(6):3387-3396. PubMed ID: 27779717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.